Sellas Life Sciences Group Inc expected to post a loss of 29 cents a share - Earnings Preview

Sellas Life Sciences

08/05/2023 12:47

* Sellas Life Sciences Group Inc  SLS.OQ   SLS.O  is
expected
to show a fall in quarterly revenue when it reports  results on
May 10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Sellas Life
Sciences
Group Inc is for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sellas Life
Sciences Group Inc is $6​, above​ its last closing price
of $1.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.34       -0.32      -0.43     Missed  -34.4
 Sep. 30 2022  -0.39       -0.39      -0.34     Beat    12.1
 Jun. 30 2022  -0.35       -0.35      -0.41     Missed  -17.1​
 Mar. 31 2022  -0.38       -0.38      -1.05     Missed  -176.3
 ​​Dec.        -0.45       -0.41      -0.42     Missed  -2.4
 31 2021                                                
 Sep. 30 2021  -0.41       -0.38      -0.45     Missed  -19.5​
 Jun. 30 2021  -0.40       -0.39      -0.30     Beat    23.1
 Mar. 31 2021              -0.27      -0.16     Beat    40.7
 This summary was machine generated May 8 at 11:47 GMT.  All
figures in US dollars  unless otherwise stated